Analysts Set Zura Bio Limited (NASDAQ:ZURA) Price Target at $19.75

Zura Bio Limited (NASDAQ:ZURA) has received an average recommendation of “Buy” from the six ratings firms that are covering the firm, MarketBeat reports. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $19.75.

A number of research analysts have commented on the company. Oppenheimer upped their price objective on Zura Bio from $16.00 to $21.00 and gave the company an “outperform” rating in a report on Friday, May 10th. Cantor Fitzgerald started coverage on shares of Zura Bio in a research note on Wednesday, June 12th. They issued an “overweight” rating for the company. Finally, Piper Sandler started coverage on shares of Zura Bio in a research report on Friday, May 3rd. They set an “overweight” rating and a $26.00 target price on the stock.

Zura Bio Stock Down 1.2 %

Shares of ZURA stock opened at $3.38 on Friday. Zura Bio has a 52 week low of $2.00 and a 52 week high of $11.13. The company has a 50-day simple moving average of $4.40 and a 200 day simple moving average of $3.93.

Zura Bio (NASDAQ:ZURA) last issued its quarterly earnings data on Thursday, May 9th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.21. Equities research analysts predict that Zura Bio will post -0.53 earnings per share for the current year.

Insider Activity at Zura Bio

In other news, Director Van Amstel Arnout Ploos acquired 80,000 shares of Zura Bio stock in a transaction on Friday, May 17th. The shares were purchased at an average cost of $6.20 per share, for a total transaction of $496,000.00. Following the completion of the purchase, the director now directly owns 100,000 shares of the company’s stock, valued at approximately $620,000. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In other Zura Bio news, Director Amit Munshi purchased 159,744 shares of the firm’s stock in a transaction dated Monday, April 22nd. The shares were bought at an average price of $3.13 per share, for a total transaction of $499,998.72. Following the purchase, the director now owns 777,384 shares in the company, valued at approximately $2,433,211.92. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Van Amstel Arnout Ploos purchased 80,000 shares of the stock in a transaction dated Friday, May 17th. The shares were acquired at an average cost of $6.20 per share, with a total value of $496,000.00. Following the acquisition, the director now directly owns 100,000 shares in the company, valued at approximately $620,000. The disclosure for this purchase can be found here. Insiders purchased a total of 250,926 shares of company stock valued at $1,030,998 over the last quarter. 15.80% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of ZURA. Armistice Capital LLC lifted its holdings in shares of Zura Bio by 15.4% in the fourth quarter. Armistice Capital LLC now owns 1,824,000 shares of the company’s stock worth $8,518,000 after acquiring an additional 244,000 shares during the last quarter. Affinity Asset Advisors LLC bought a new position in Zura Bio in the 1st quarter valued at approximately $1,157,000. Forefront Analytics LLC boosted its position in Zura Bio by 46.8% in the fourth quarter. Forefront Analytics LLC now owns 21,229 shares of the company’s stock valued at $99,000 after buying an additional 6,765 shares in the last quarter. Finally, Lynx1 Capital Management LP bought a new stake in shares of Zura Bio during the third quarter worth $65,000. Institutional investors own 61.14% of the company’s stock.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.